Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women’s health practice

References

• MorinSNLixLMLeslieWDThe importance of previous fracture site on osteoporosis diagnosis and incident fractures in womenJ Bone Miner Res20142971675168024535832
   PubMed Web of Science ®Google Scholar
• CheungAMDetskyASOsteoporosis and fractures: missing the bridge?JAMA2008299121468147018364489
   PubMed Web of Science ®Google Scholar
• DempsterDWAnatomy and functions of the adult skeletonFavusMJPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism6th edAmes, IowaASBMR2006711
   Google Scholar
• SeemanEDelmasPDBone quality – the material and structural basis of bone strength and fragilityN Engl J Med2006354212250226116723616
   PubMed Web of Science ®Google Scholar
• HochbergMCGreenspanSWasnichRDMillerPThompsonDERossPDChanges in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agentsJ Clin Endocrinol Metab20028741586159211932287
   PubMed Web of Science ®Google Scholar
• WasnichRDMillerPDAntifracture efficacy of antiresorptive agents are related to changes in bone densityJ Clin Endocrinol Metab200085123123610634392
   PubMed Web of Science ®Google Scholar
• CheungAMTileLCardewSBone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trialLancet Oncol201213327528422318095
   PubMed Web of Science ®Google Scholar
• MayhewPMThomasCDClementJGRelation between age, femoral neck cortical stability, and hip fracture riskLancet2005366948012913516005335
   PubMed Web of Science ®Google Scholar
• MacdonaldHMNishiyamaKKKangJHanleyDABoydSKAge-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT studyJ Bone Miner Res2011261506220593413
   PubMed Web of Science ®Google Scholar
• HansenMAOvergaardKRiisBJChristiansenCRole of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year studyBMJ199130368089619641954420
   PubMed Web of Science ®Google Scholar
• BurghardtAJKazakiaGJSodeMde PappAELinkTMMajumdarSA longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnoverJ Bone Miner Res201025122558257120564242
   PubMed Web of Science ®Google Scholar
• XuWPereraSMedichDHeight loss, vertebral fractures, and the misclassification of osteoporosisBone201148230731120870048
   PubMed Web of Science ®Google Scholar
• KhoslaSPacificiEstrogen deficiency, postmenopausal osteoporosis, and age-related bone lossMarcusRFeldmanDDempsterDWLuckeyMCauleyJAOsteoporosis4th edSan DiegoAcademic Press201311131136
   Google Scholar
• SambrookPCooperCOsteoporosisLancet200636795272010201816782492
   PubMed Web of Science ®Google Scholar
• MacNeilJABoydSKLoad distribution and the predictive power of morphological indices in the distal radius and tibia by high resolution peripheral quantitative computed tomographyBone200741112913717442649
   PubMed Web of Science ®Google Scholar
• BurgeRDawson-HughesBSolomonDHWongJBKingATostesonAIncidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res200722346547517144789
   PubMed Web of Science ®Google Scholar
• BessetteLSte-MarieLGJeanSThe care gap in diagnosis and treatment of women with a fragility fractureOsteoporos Int2008191798617641811
   PubMed Web of Science ®Google Scholar
• ZebazeRMGhasem-ZadehABohteAIntracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional studyLancet201037597271729173620472174
   PubMed Web of Science ®Google Scholar
• BurghardtAJKazakiaGJRamachandranSLinkTMMajumdarSAge- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibiaJ Bone Miner Res201025598399319888900
   PubMed Web of Science ®Google Scholar
• AhlborgHGJohnellOTurnerCHRannevikGKarlssonMKBone loss and bone size after menopauseN Engl J Med2003349432733412878739
   PubMed Web of Science ®Google Scholar
• SeemanEPeriosteal bone formation – a neglected determinant of bone strengthN Engl J Med2003349432032312878736
   PubMed Web of Science ®Google Scholar
• LauretaniFBandinelliSGriswoldMELongitudinal changes in BMD and bone geometry in a population-based studyJ Bone Miner Res200823340040817997708
   PubMed Web of Science ®Google Scholar
• SzulcPSeemanEDuboeufFSornay-RenduEDelmasPDBone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal womenJ Bone Miner Res200621121856186317002580
   PubMed Web of Science ®Google Scholar
• CranneyAJamalSATsangJFJosseRGLeslieWDLow bone mineral density and fracture burden in postmenopausal womenCMAJ2007177657558017846439
   PubMed Web of Science ®Google Scholar
• BoussonVBergotCSutterBTrabecular bone score: where are we now?Joint Bone Spine201582532032525921803
   PubMed Web of Science ®Google Scholar
• PapaioannouAMorinSCheungAM2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryCMAJ2010182171864187320940232
   PubMed Web of Science ®Google Scholar
• UnnanuntanaAGladnickBPDonnellyELaneJMThe assessment of fracture riskJ Bone Joint Surg Am201092374375320194335
   PubMed Web of Science ®Google Scholar
• Van StaaTPLaanRFBartonIPCohenSReidDMCooperCBone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapyArthritis Rheum200348113224322914613287
   PubMed Web of Science ®Google Scholar
• AminSGabrielSEAchenbachSJAtkinsonEJMeltonLJ3rdAre young women and men with rheumatoid arthritis at risk for fragility fractures? A population-based studyJ Rheumatol201340101669167623950189
   PubMed Web of Science ®Google Scholar
• LeslieWDLixLMLangsetmoLConstruction of a FRAX(R) model for the assessment of fracture probability in Canada and implications for treatmentOsteoporos Int201122381782721161509
   PubMed Web of Science ®Google Scholar
• PapaioannouAMorinSCheungAMClinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada: Background and Technical Report Available from: http://www.osteoporosis.ca/multimedia/pdf/Osteoporosis_Guidelines_2010_Background_And_Technical_Report.pdfAccessed July 2016
   Google Scholar
• FRAX fracture risk assessment tool output can now be modified by TBS [updated May 15, 2015]. Available from: https://www.iofbonehealth.org/news/frax-fracture-risk-assessment-tool-output-can-now-be-modified-tbsAccessed June 2016
   Google Scholar
• LewieckiEMCummingsSRCosmanFTreat-to-target for osteoporosis: is now the time?J Clin Endocrinol Metab201398394695323337726
   PubMed Web of Science ®Google Scholar
• MuncieHLeblancLLMonitoring osteoporosis treatment: DXA should not be routinely repeatedAm Fam Phys2010827752754
   Web of Science ®Google Scholar
• WheaterGElshahalyMTuckSPDattaHKvan LaarJMThe clinical utility of bone marker measurements in osteoporosisJ Transl Med20131120123984630
   PubMed Web of Science ®Google Scholar
• KurodaTShirakiMShirakiYTanakaSThe importance of absolute bone mineral density in the assessment of antiresorptive agents used for the prevention of osteoporotic fracturesJ Clin Densitom201215439239822521539
   PubMed Web of Science ®Google Scholar
• AustinMYangYCVittinghoffERelationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fracturesJ Bone Miner Res201227368769322095631
   PubMed Web of Science ®Google Scholar
• MillerPCummingsSReginsterJYRelationship between changes in BMD and incidence of Fracture with 6 years of denosumab treatmentPresented at: ASMBR Annual MeetingMinneapolis, MNOctober 14, 2012 Abstract 1099; Presentation
   Google Scholar
• JacquesRMBoonenSCosmanFRelationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT)J Bone Miner Res20122781627163422532515
   PubMed Web of Science ®Google Scholar
• EngelkeKAssessment of bone quality and strength with new technologiesCurr Opin Endocrinol Diabetes Obes201219647448223076043
   PubMedGoogle Scholar
• EngelkeKAdamsJEArmbrechtGClinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positionsJ Clin Densitom200811112316218442757
   PubMed Web of Science ®Google Scholar
• NishiyamaKKShaneEClinical imaging of bone microarchitecture with HR-pQCTCurr Osteoporos Rep201311214715523504496
   PubMed Web of Science ®Google Scholar
• CheungAMAdachiJDHanleyDAHigh-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working GroupCurr Osteoporos Rep201311213614623525967
   PubMed Web of Science ®Google Scholar
• DhainautAHoffMSyversenUHaugebergGCortical hand bone porosity and its association with distal radius fracture in middle aged and elderly womenPLoS One201387e6840523844197
   PubMed Web of Science ®Google Scholar
• WongACaMos Bone Quality Studies: Plans & Pilot Studies2011 Available from: http://www.camris.ca/med/document/WongAKO-SaskatoonCaMosPilots-1-7.pdfAccessed September 2014
   Google Scholar
• SCANCO MedicalXtremeCT II Available from: http://www.scanco.ch/en/systems-solutions/clinical-microct/xtremect1.htmlAccessed September 2015
   Google Scholar
• LeeDCGilsanzVWrenTALimitations of peripheral quantitative computed tomography metaphyseal bone density measurementsJ Clin Endocrinol Metab200792114248425317684050
   PubMed Web of Science ®Google Scholar
• BouxseinMLTechnology insight: noninvasive assessment of bone strength in osteoporosisNat Clin Pract Rheumatol20084631031818431371
   PubMedGoogle Scholar
• NaylorKEMcCloskeyEVEastellRYangLUse of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fractureJ Bone Miner Res20132851014102123281096
   PubMed Web of Science ®Google Scholar
• KazakiaGJBurghardtAJLinkTMMajumdarSVariations in morphological and biomechanical indices at the distal radius in subjects with identical BMDJ Biomech201144225726621071031
   PubMed Web of Science ®Google Scholar
• BoutroySBouxseinMLMunozFDelmasPDIn vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomographyJ Clin Endocrinol Metab200590126508651516189253
   PubMed Web of Science ®Google Scholar
• SheuYZmudaJMBoudreauRMBone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) studyJ Bone Miner Res2011261637120593412
   PubMed Web of Science ®Google Scholar
• GenantHKEngelkeKHanleyDADenosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral densityBone201047113113920399288
   PubMed Web of Science ®Google Scholar
• OrwollESMarshallLMNielsonCMFinite element analysis of the proximal femur and hip fracture risk in older menJ Bone Miner Res200924347548319049327
   PubMed Web of Science ®Google Scholar
• KopperdahlDLAspelundTHoffmannPFAssessment of incident spine and hip fractures in women and men using finite element analysis of CT scansJ Bone Miner Res201429357058023956027
   PubMed Web of Science ®Google Scholar
• WattsNBClinical utility of biochemical markers of bone remodelingClin Chem1999458 Pt 21359136810430819
   PubMed Web of Science ®Google Scholar
• CoenGBallantiPBonucciEBone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patientsNephrol Dial Transplant1998139229423029761512
   PubMed Web of Science ®Google Scholar
• BurchJRiceSYangHSystematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groupsHealth Technol Assess20141811118024534414
   PubMed Web of Science ®Google Scholar
• Funck-BrentanoTBiverEChopinFClinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic reviewSemin Arthritis Rheum201141215716921507464
   PubMed Web of Science ®Google Scholar
• BrownJPPrinceRLDealCComparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJ Bone Miner Res200924115316118767928
   PubMed Web of Science ®Google Scholar
• DelmasPDMunozFBlackDMEffects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosisJ Bone Miner Res20092491544155119338427
   PubMed Web of Science ®Google Scholar
• VasikaranSEastellRBruyereOMarkers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standardsOsteoporos Int201122239142021184054
   PubMed Web of Science ®Google Scholar
• CairoliEEller-VainicherCUlivieriFMFactors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosisOsteoporos Int20142541401141024510095
   PubMed Web of Science ®Google Scholar
• HanleyDAAdachiJDBellABrownVDenosumab: mechanism of action and clinical outcomesInt J Clin Pract201266121139114622967310
   PubMed Web of Science ®Google Scholar
• BoonenSFerrariSMillerPDPostmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk – a perspectiveJ Bone Miner Res201227596397422467094
   PubMed Web of Science ®Google Scholar
• BrownJPAlbertCNassarBABone turnover markers in the management of postmenopausal osteoporosisClin Biochem20094210–1192994219362543
   PubMed Web of Science ®Google Scholar
• BaronRFerrariSRussellRGDenosumab and bisphosphonates: different mechanisms of action and effectsBone201148467769221145999
   PubMed Web of Science ®Google Scholar
• KendlerDLRouxCBenhamouCLEffects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapyJ Bone Miner Res2010251728119594293
   PubMed Web of Science ®Google Scholar
• RouxCHofbauerLCHoPRDenosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label studyBone201458485424141036
   PubMed Web of Science ®Google Scholar
• SeemanEDelmasPDHanleyDAMicroarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronateJ Bone Miner Res20102581886189420222106
   PubMed Web of Science ®Google Scholar
• ZebazeRMLibanatiCAustinMDiffering effects of denosumab and alendronate on cortical and trabecular boneBone20145917317924275677
   PubMed Web of Science ®Google Scholar
• FiroozabadiRMorshedSQualitative and quantitative assessment of bone fragility and fracture healing using conventional radiography and advanced imaging technologies – focus on wrist fractureJ Orthop Trauma2008228 SupplS83S9018753895
   PubMed Web of Science ®Google Scholar
• WahnerHWEastellRRiggsBLBone mineral density of the radius: where do we stand?J Nucl Med19852611133913414056930
   PubMed Web of Science ®Google Scholar
• FerrariSAdachiJDLippunerKFurther reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 yearsOsteoporos Int201526122763277126068295
   PubMed Web of Science ®Google Scholar
• BlackDMReidIRBoonenSThe effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT)J Bone Miner Res201227224325422161728
   PubMed Web of Science ®Google Scholar
• BoneHGHoskingDDevogelaerJPTen years’ experience with alendronate for osteoporosis in postmenopausal womenN Engl J Med2004350121189119915028823
   PubMed Web of Science ®Google Scholar
• MellstromDDSorensenOHGoemaereSRouxCJohnsonTDChinesAASeven years of treatment with risedronate in women with postmenopausal osteoporosisCalcif Tissue Int200475646246815455188
   PubMed Web of Science ®Google Scholar
• PapapoulosSLippunerKRouxCThe effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension studyOsteoporos Int201526122773278326202488
   PubMed Web of Science ®Google Scholar
• HuangAJChangCYThomasBJMacMahonPJPalmerWEUsing cone-beam CT as a low-dose 3D imaging technique for the extremities: initial experience in 50 subjectsSkeletal Radiol201544679780925652734
   PubMed Web of Science ®Google Scholar